E-QURE CORP. (OTCMKTS:EQUR) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
On January 8, 2017, E-Qure Corp., a Delaware corporation (the "Registrant") entered into a five-year distribution agreement (the "Distribution Agreement") with TekMedica SAS, organized under the laws of Colombia ("TekMedica" or the "Distributor"). to the Distribution Agreement, the Registrant granted TekMedica the exclusive rights to distribute the Registrant’s medical device for the treatment of chronic wounds (the "BST Device™") and the accompanying disposable electrodes (sometimes collectively, the "Products") in Colombia (the "Territory").
The Distribution Agreement provides that Registrant will provide Distributor with supplies of the BST Devicee™ and disposable electrode for treatment of patients in hospitals, long-term care facilities, medical centers and out-patient clinics. The Distributor will make an initial advance payment to be applied against the first year’s quota together with an initial order supported by a Letter of Credit with subsequent orders as part of the quota, as set forth in the Distribution Agreement, with minimum annual quota’s during the five-year term.
The Distributor will be responsible for securing any product certification, permit, license or approval that may be required in the Territory for the marketing, sale, sublicensing and delivery and use of the BST Devise and Products in the Territory.
About E-QURE CORP. (OTCMKTS:EQUR)
E-Qure Corp. owns intellectual property (IP) of technology of wound healing device. The IP assets, including the wound healing device, are designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). The BST Device implements electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The BST Device, using electrodes affixed around the opposing sides of the wound, emits an electrical field around the wound and therefore mimics the electrochemical physiology principle and induces local cell regeneration. The BST Device is used to treat severe stage II, as well as stage III and IV wounds, including pressure ulcers, diabetic ulcers and venous ulcers. The BST Device is a device for adjunctive therapy in wound healing. The BST Device is able to automatically adjust the electric pulse amplitude based on a patient’s impedance reading. E-QURE CORP. (OTCMKTS:EQUR) Recent Trading Information
E-QURE CORP. (OTCMKTS:EQUR) closed its last trading session 00.000 at 0.130 with 5,450 shares trading hands.